You’re offline. This is a read only version of the page.
ElasmogenCaroline Barelle
Elasmogen @ElasmogenLtd
University of Aberdeen
Therapeutic antibody sales were $82.2 Bn in 2014 and continue to grow. These biologics drugs are successful but limited due to their large complex structures and cost of goods. SoloMERS is a next generation therapeutic biologics with all the specific binding properties of antibodies but <10% of the size. They are inherently stable, soluble molecules that can be readily formatted to bind multiple targets and due to their size can penetrate further into tissues eg tumours. Elasmogen has succeeded in developing soloMERs and has programs to target solid tumours and to treat inflammatory eye disease.
Read the full case study here.
https://www.elasmogen.com/